{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:56:07Z","timestamp":1792292167480,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2238-9","type":"journal-article","created":{"date-parts":[[2016,3,8]],"date-time":"2016-03-08T10:11:11Z","timestamp":1457431871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000\u20132013"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2621-5494","authenticated-orcid":false,"given":"Tumas","family":"Beinortas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilma","family":"Tavorien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadas","family":"\u017dvirblis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolandas","family":"Gerbutavi\u010dius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindaugas","family":"Jurgutis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laimonas","family":"Gri\u0161kevi\u010dius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,8]]},"reference":[{"issue":"5","key":"2238_CR1","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8(5):935\u201342.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"2238_CR2","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bjorkholm","year":"2011","unstructured":"Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29(18):2514\u201320.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2238_CR3","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.3109\/10428194.2014.974046","volume":"56","author":"A Penot","year":"2015","unstructured":"Penot A, Preux PM, Le Guyader S, Collignon A, Herry A, Dufour V, et al. Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009. Leuk Lymphoma. 2015;56(6):1771\u20137.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2238_CR4","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","volume":"103","author":"H Kantarjian","year":"2004","unstructured":"Kantarjian H, Talpaz M, O\u2019Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004;103(8):2873\u20138.","journal-title":"Blood"},{"issue":"1","key":"2238_CR5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2002-02-0545","volume":"101","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, Cortes JE, O\u2019Brien S, Giles F, Garcia-Manero G, Faderl S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 2003;101(1):97\u2013100.","journal-title":"Blood"},{"issue":"9","key":"2238_CR6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645\u201352.","journal-title":"N Engl J Med"},{"issue":"11","key":"2238_CR7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2\u00a0years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029\u201335.","journal-title":"Lancet Oncol"},{"issue":"22","key":"2238_CR8","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1182\/blood-2013-03-490003","volume":"121","author":"C Abboud","year":"2013","unstructured":"Abboud C, Berman E, Cohen A, Cortes J, DeAngelo D, Deininger M, et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439\u201342.","journal-title":"Blood"},{"issue":"Suppl 2","key":"2238_CR9","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1007\/s00277-015-2319-x","volume":"94","author":"RM Conti","year":"2015","unstructured":"Conti RM, Padula WV, Larson RA. Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. Ann Hematol. 2015;94 Suppl 2:S249\u2013257.","journal-title":"Ann Hematol"},{"issue":"1","key":"2238_CR10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.7705\/biomedica.v34i1.1446","volume":"34","author":"M Romero","year":"2014","unstructured":"Romero M, Chavez D, De Los RM, Alvis-Guzman N. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012. Biomedica. 2014;34(1):48\u201359.","journal-title":"Biomedica"},{"issue":"5","key":"2238_CR11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1634\/theoncologist.2010-0393","volume":"16","author":"D Pulte","year":"2011","unstructured":"Pulte D, Gondos A, Redaniel MT, Brenner H. Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. Oncologist. 2011;16(5):663\u201371.","journal-title":"Oncologist"},{"issue":"7","key":"2238_CR12","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M Hoglund","year":"2013","unstructured":"Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122(7):1284\u201392.","journal-title":"Blood"},{"issue":"6","key":"2238_CR13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/ejh.12468","volume":"94","author":"D Pulte","year":"2015","unstructured":"Pulte D, Redaniel MT, Bird J, Jeffreys M. Survival for patients with chronic leukemias in the US and Britain: Age-related disparities and changes in the early 21st century. Eur J Haematol. 2015;94(6):540\u20135.","journal-title":"Eur J Haematol"},{"issue":"2","key":"2238_CR14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0609.2011.01637.x","volume":"87","author":"E Faber","year":"2011","unstructured":"Faber E, Muzik J, Koza V, Demeckova E, Voglova J, Demitrovicova L, et al. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000--a report from the population-based CAMELIA Registry. Eur J Haematol. 2011;87(2):157\u201368.","journal-title":"Eur J Haematol"},{"issue":"12","key":"2238_CR15","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1634\/theoncologist.2012-0197","volume":"17","author":"D Chihara","year":"2012","unstructured":"Chihara D, Ito H, Matsuda T, Katanoda K, Shibata A, Saika K, et al. Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S. Oncologist. 2012;17(12):1547\u201350.","journal-title":"Oncologist"},{"key":"2238_CR16","volume-title":"Basic & clinical biostatistics","author":"B Dawson","year":"2001","unstructured":"Dawson B, Trapp RG. Basic & clinical biostatistics. Monterey: McGraw-Hill; 2001."},{"key":"2238_CR17","first-page":"1","volume-title":"Cancer incidence in five continents","author":"M Boniol","year":"2008","unstructured":"Boniol M, Heanue M. Age-standardisation and denominators. In: Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, editors. Cancer incidence in five continents. 2008. p. 1\u2013837."},{"key":"2238_CR18","unstructured":"United Nations. World Population Prospects, the 2015 Revision [ http:\/\/esa.un.org\/wpp\/Excel-Data\/population.htm ]"},{"issue":"1","key":"2238_CR19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/sim.1597","volume":"23","author":"PW Dickman","year":"2004","unstructured":"Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med. 2004;23(1):51\u201364.","journal-title":"Stat Med"},{"issue":"282","key":"2238_CR20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53(282):457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"2238_CR21","volume-title":"Methodological note","author":"F Ederer","year":"1959","unstructured":"Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. In: Methodological note. 1959."},{"issue":"6","key":"2238_CR22","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffmann","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29(6):1336\u201343.","journal-title":"Leukemia"},{"issue":"2","key":"2238_CR23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.2012.064014","volume":"98","author":"M Maynadie","year":"2013","unstructured":"Maynadie M, De Angelis R, Marcos-Gragera R, Visser O, Allemani C, Tereanu C, et al. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study. Haematologica. 2013;98(2):230\u20138.","journal-title":"Haematologica"},{"issue":"19","key":"2238_CR24","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724\u201334.","journal-title":"Blood"},{"issue":"11","key":"2238_CR25","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","volume":"105","author":"A Smith","year":"2011","unstructured":"Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer. 2011;105(11):1684\u201392.","journal-title":"Br J Cancer"},{"issue":"7","key":"2238_CR26","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","volume":"54","author":"Y Chen","year":"2013","unstructured":"Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma. 2013;54(7):1411\u20137.","journal-title":"Leuk Lymphoma"},{"key":"2238_CR27","unstructured":"Chronic Myeloid Leukemia [ http:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html ]"},{"issue":"6","key":"2238_CR28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/2040620715607416","volume":"6","author":"S Giri","year":"2015","unstructured":"Giri S, Pathak R, Martin MG, Bhatt VR. Characteristics and survival of BCR\/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database. Therapeutic advances in hematology. 2015;6(6):308\u201312.","journal-title":"Therapeutic advances in hematology"},{"issue":"11","key":"2238_CR29","first-page":"1566","volume":"91","author":"M Breccia","year":"2006","unstructured":"Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F, Alimena G. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica. 2006;91(11):1566\u20138.","journal-title":"Haematologica"},{"issue":"23","key":"2238_CR30","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u201317.","journal-title":"N Engl J Med"},{"issue":"9","key":"2238_CR31","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","volume":"119","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, O\u2019Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119(9):1981\u20137.","journal-title":"Blood"},{"key":"2238_CR32","doi-asserted-by":"crossref","unstructured":"Pfirrmann M, Saussele S, Baccarani M, Guilhot J, Cervantes F, Ossenkoppele GJ, Lindoerfer D, Hoffmann VS, Castagnetti F, Hehlmann R et al. Survival and Prognosis in Patients with First-Line Imatinib Treatment Under Particular Consideration of Death Due to Chronic Myeloid Leukemia. Blood. 2014;124(21):153.","DOI":"10.1182\/blood.V124.21.153.153"},{"issue":"16","key":"2238_CR33","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1182\/blood-2013-11-539742","volume":"123","author":"M Lauseker","year":"2014","unstructured":"Lauseker M, Hasford J, Pfirrmann M, Hehlmann R. The impact of health care settings on survival time of patients with chronic myeloid leukemia. Blood. 2014;123(16):2494\u20136.","journal-title":"Blood"},{"issue":"9","key":"2238_CR34","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","volume":"15","author":"M Sant","year":"2014","unstructured":"Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol. 2014;15(9):931\u201342.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2238_CR35","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3109\/10428194.2014.947610","volume":"56","author":"G Osca-Gelis","year":"2015","unstructured":"Osca-Gelis G, Puig-Vives M, Saez M, Gallardo D, Lloveras N, Guardia R, et al. Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study. Leuk Lymphoma. 2015;56(4):896\u2013902.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2238_CR36","doi-asserted-by":"crossref","first-page":"e004266","DOI":"10.1136\/bmjopen-2013-004266","volume":"4","author":"AG Smith","year":"2014","unstructured":"Smith AG, Painter D, Howell DA, Evans P, Smith G, Patmore R, et al. Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ open. 2014;4(1):e004266.","journal-title":"BMJ open"},{"key":"2238_CR37","unstructured":"Trends in incidence and outcome for haematological cancers in England: 2001-2010. In: National cancer intelligence network. 2014."},{"issue":"7","key":"2238_CR38","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon FX, Guilhot F, Deininger M, Fava C, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103(7):553\u201361.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2238_CR39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1161\/01.HYP.0000202487.68969.f7","volume":"47","author":"MW Schellings","year":"2006","unstructured":"Schellings MW, Baumann M, van Leeuwen RE, Duisters RF, Janssen SH, Schroen B, et al. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension. 2006;47(3):467\u201374.","journal-title":"Hypertension"},{"issue":"8","key":"2238_CR40","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkela","year":"2006","unstructured":"Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908\u201316.","journal-title":"Nat Med"},{"key":"2238_CR41","doi-asserted-by":"crossref","unstructured":"Kurtovic-Kozaric A, Hasic A, Radich JP, Bijedic V, Nefic H, Eminovic I, Kurtovic S, Colakovic F, Kozaric M, Vranic S et al. The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients. British journal of haematology. 2015;172(3):420\u20137.","DOI":"10.1111\/bjh.13843"},{"issue":"11","key":"2238_CR42","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.leukres.2010.03.033","volume":"34","author":"DW Kim","year":"2010","unstructured":"Kim DW, Banavali SD, Bunworasate U, Goh YT, Ganly P, Huang H, et al. Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res. 2010;34(11):1459\u201371.","journal-title":"Leuk Res"},{"issue":"8","key":"2238_CR43","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.amjmed.2010.03.018","volume":"123","author":"CL Wiggins","year":"2010","unstructured":"Wiggins CL, Harlan LC, Nelson HE, Stevens JL, Willman CL, Libby EN, et al. Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia. Am J Med. 2010;123(8):764. e761-769.","journal-title":"Am J Med"},{"issue":"1","key":"2238_CR44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Saussele","year":"2015","unstructured":"Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood. 2015;126(1):42\u20139.","journal-title":"Blood"},{"issue":"21","key":"2238_CR45","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","volume":"117","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood. 2011;117(21):5591\u20139.","journal-title":"Blood"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2238-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T20:56:47Z","timestamp":1600289807000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-2407\/16\/198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,8]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2238"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2238-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,8]]},"article-number":"198"}}